This Week in Endocrinology — Aug 4, 2026

Welcome to This Week in Endocrinology. This week we're covering ten notable papers spanning pediatric and genetic endocrinology, diabetes care and risk prediction, and novel management strategies in thyroid and adrenal diseases. Let's dive in.

We begin with new insights into pediatric endocrinology and genetic syndromes, starting with a phase three trial published in The Journal of Clinical Endocrinology and Metabolism. For girls with Turner syndrome, daily growth hormone injections represent a substantial treatment burden. The REAL8 trial evaluated once-weekly somapacitan, a long-acting growth hormone, against daily growth hormone in one hundred and five treatment-naive prepubertal girls [1]. At fifty-two weeks, the once-weekly formulation proved non-inferior, with a mean height velocity of nine point zero centimeters per year compared to nine point five centimeters per year in the daily group. Insulin-like growth factor-one standard deviation scores and safety profiles were highly comparable between the two groups, suggesting once-weekly somapacitan is a viable option to reduce treatment burden. In the same journal, researchers investigated the melanocortin-four receptor agonist setmelanotide in patients with Bardet-Biedl syndrome, a rare ciliopathy characterized by early-onset obesity [10]. In a prospective observational study of fifty-eight patients, setmelanotide not only reduced body mass index and hemoglobin A1c over six months but also modulated multiple endocrine axes. The treatment was associated with age-dependent increases in gonadotropins, testosterone, and estradiol, alongside an increase in insulin-like growth factor-one and a decrease in thyroid-stimulating hormone without changes in peripheral thyroid hormones. These findings suggest the melanocortin-four receptor pathway acts as a key integrator of metabolic and endocrine function, yielding therapeutic effects that are partially independent of weight loss. Shifting to early life development, a bidirectional cohort study in the journal Thyroid evaluated the impact of maternal Graves' disease on offspring [8]. Among one hundred and fifty-nine neonates, over thirty-seven percent experienced thyroid dysfunction, most commonly hyperthyrotropinemia. Higher maternal third-trimester thyrotropin receptor antibody levels were independently associated with both neonatal thyroid dysfunction and abnormal neurodevelopmental screening results at twenty-four months. Interestingly, mediation analysis suggested that the association with abnormal neurodevelopment was not primarily explained by neonatal thyroid-stimulating hormone levels alone, emphasizing the need for close monitoring of these high-risk pregnancies.

Next, we turn to diabetes management, risk prediction, and associated complications. Continuous glucose monitoring, or CGM, has seen rapidly expanding use. A systematic review in JAMA Internal Medicine examined the evidence for continuous glucose monitoring beyond type one diabetes [2]. In adults with type two diabetes, continuous glucose monitoring was associated with a modest but consistent reduction in hemoglobin A1c of approximately zero point three percent compared to finger-stick monitoring or usual care. However, the authors found only limited and indirect evidence supporting its use in patients with type two diabetes who are not on glucose-lowering therapy, or in those with prediabetes or obesity, suggesting that continuous glucose monitoring should be deployed as a targeted problem-solving tool rather than a default intervention. For patients already living with diabetes, the presence of metabolic dysfunction-associated steatotic liver disease, or MASLD, is a growing concern. A critical reappraisal in Diabetologia argues that while MASLD, particularly with significant fibrosis, shares many metabolic abnormalities with type two diabetes, current evidence suggests it acts as a disease risk enhancer rather than an independent risk factor for microvascular and macrovascular complications [6]. The authors highlight major limitations in existing observational studies, such as inadequate control for cardiometabolic risk factors, and call for more proactive risk stratification. Looking at risk prediction before diabetes develops, another study in Diabetologia explored the utility of polygenic scores in predicting type one and type two diabetes in women with a history of gestational diabetes [7]. Following three hundred and seventy women over a median of thirty years, researchers found that a polygenic score for type one diabetes, when combined with clinical risk factors during pregnancy, highly predicted the future development of type one diabetes, achieving an area under the curve of zero point eight eight seven. In contrast, the polygenic score for type two diabetes showed no predictive ability, suggesting that genetic profiling may be uniquely valuable for identifying post-gestational patients at risk for autoimmune diabetes.

In thyroid care, we see critical clinical and economic evaluations of modern interventions. A retrospective micro-costing analysis published in the journal Thyroid compared thyroid radiofrequency ablation with hemithyroidectomy across a one-year care cycle in Toronto, Canada [5]. The base-case cost for radiofrequency ablation was nearly thirty percent lower than the mean cost of all hemithyroidectomies, representing a savings of over sixteen hundred Canadian dollars per patient. While radiofrequency ablation eliminates operating room and inpatient admission costs, sensitivity analyses revealed that its economic advantage is highly sensitive to the rates of nodule regrowth requiring repeat ablation or delayed surgery, underscoring the need for careful patient selection. For patients with advanced thyroid disease, managing rare complications remains a challenge. International multicenter data, also in Thyroid, characterized brain metastases from non-anaplastic follicular cell-derived thyroid carcinoma in one hundred and eighty-nine patients [9]. The median overall survival after brain metastasis diagnosis was fifteen months. The researchers developed and validated a disease-specific Graded Prognostic Assessment score, identifying age over seventy-five, poor performance status, papillary histology, extracranial metastases, and having four or more brain metastases as independent predictors of shorter survival. This new score offers clinicians a structured framework to stratify prognosis and individualize therapy.

Finally, we highlight novel therapeutic delivery and safety evaluations. Adrenal crisis is a life-threatening emergency requiring rapid glucocorticoid administration, yet many patients fail to self-inject hydrocortisone due to anxiety or complexity. A pharmacokinetic study in the European Journal of Endocrinology evaluated inhaled nebulized prednisolone sodium succinate in twelve healthy participants as a potential alternative [3]. The target therapeutic plasma concentration of two hundred nanomoles per liter was achieved rapidly, with median times of seventeen minutes for a fifty-six milligram dose and just nine minutes for a one hundred and twelve milligram dose. These findings demonstrate rapid pulmonary absorption and suggest that an inhaled formulation could offer a highly feasible outpatient alternative for emergency management. In the same journal, researchers conducted a comprehensive safety review of glucagon-like peptide-one receptor agonists in patients with neuroendocrine neoplasms [4]. Despite historical concerns and black-box warnings related to rodent studies of medullary thyroid carcinoma, the review of retrospective studies, clinical trials, and cancer registries did not support a generalized increase in neuroendocrine neoplasms with these therapies. However, due to remaining evidence gaps, particularly regarding patients with multiple endocrine neoplasia type one, the authors advise a cautious, monitored approach when initiating these agents in patients with a known predisposition to neuroendocrine tumors.

If you only have time for one paper this week, make it the phase three trial of once-weekly somapacitan in girls with Turner syndrome, published in The Journal of Clinical Endocrinology and Metabolism [1]. This study provides robust evidence that a once-weekly long-acting growth hormone is non-inferior to daily injections, offering a major advancement in reducing treatment burden and improving quality of life for these young patients.

Here are the key takeaways from this week in Endocrinology. First, once-weekly somapacitan is non-inferior to daily growth hormone in prepubertal girls with Turner syndrome, maintaining a similar safety and insulin-like growth factor-one profile. Second, continuous glucose monitoring in type two diabetes provides a modest average hemoglobin A1c reduction of zero point three percent, but its routine use in patients not on insulin, or those with prediabetes or obesity, lacks strong supportive evidence. Third, higher maternal third-trimester thyrotropin receptor antibody levels in Graves' disease are independently associated with both neonatal thyroid dysfunction and abnormal offspring neurodevelopment at twenty-four months. Fourth, thyroid radiofrequency ablation offers a nearly thirty percent cost savings over hemithyroidectomy, though its economic benefit depends heavily on avoiding repeat procedures or delayed surgeries. Finally, inhaled prednisolone sodium succinate is rapidly absorbed via the lungs, reaching therapeutic levels in under twenty minutes, representing a promising future alternative for outpatient adrenal crisis management.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.